Outlook Therapeutics Inc [OTLK] stock is trading at $2.37, up 8.72%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The OTLK shares have gain 15.05% over the last week, with a monthly amount glided 39.41%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Outlook Therapeutics Inc [NASDAQ: OTLK] stock has seen the most recent analyst activity on December 02, 2024, when Chardan Capital Markets downgraded its rating to a Neutral. Previously, BTIG Research upgraded its rating to Buy on March 27, 2024, and kept the price target unchanged to $50. On February 15, 2024, upgrade upgraded it’s rating to Buy but maintained its price target of $3 on the stock. Guggenheim upgraded its rating to a Buy. CapitalOne upgraded its rating to a Overweight but $5 remained the price target by the analyst firm on December 27, 2023. H.C. Wainwright downgraded its rating to Neutral for this stock on August 31, 2023, and downed its price target to $1. In a note dated August 31, 2023, Chardan Capital Markets downgraded an Neutral rating on this stock.
Outlook Therapeutics Inc [OTLK] stock has fluctuated between $0.87 and $12.85 over the past year. Outlook Therapeutics Inc [NASDAQ: OTLK] shares were valued at $2.37 at the most recent close of the market.
Analyzing the OTLK fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -2.61, Equity is 0.96 and Total Capital is 5.22. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -0.4.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.22 points at the first support level, and at 2.06 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.45, and for the 2nd resistance point, it is at 2.52.
Ratios To Look Out For
For context, Outlook Therapeutics Inc’s Current Ratio is 0.64. As well, the Quick Ratio is 0.64, while the Cash Ratio is 0.35.
Transactions by insiders
Recent insider trading involved KENYON LAWRENCE A, Chief Financial Officer, that happened on Sep 26 ’24 when 5000.0 shares were purchased. Director, Haddadin Yezan Munther completed a deal on Mar 28 ’24 to buy 1882.0 shares. Meanwhile, CHIEF COMMERCIAL OFFICER Evanson Jeff bought 62484.0 shares on Mar 07 ’24.
